S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

BioVie Stock Forecast, Price & News

+0.43 (+3.00 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $14.78
50-Day Range
MA: $35.44
52-Week Range
Now: $14.78
Volume199,024 shs
Average Volume118,716 shs
Market Capitalization$205.68 million
P/E RatioN/A
Dividend YieldN/A
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BIVI
Phone312 283 5793
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$205.68 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

1.70 out of 5 stars

Medical Sector

238th out of 1,969 stocks

Pharmaceutical Preparations Industry

111th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.43 (+3.00 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIVI News and Ratings via Email

Sign-up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BioVie (NASDAQ:BIVI) Frequently Asked Questions

Is BioVie a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioVie in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioVie stock.
View analyst ratings for BioVie
or view top-rated stocks.

What stocks does MarketBeat like better than BioVie?

Wall Street analysts have given BioVie a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioVie wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BioVie?

BioVie saw a increase in short interest in February. As of February 12th, there was short interest totaling 79,600 shares, an increase of 32.0% from the January 28th total of 60,300 shares. Based on an average trading volume of 85,100 shares, the short-interest ratio is currently 0.9 days. Approximately 3.2% of the shares of the stock are sold short.
View BioVie's Short Interest

How were BioVie's earnings last quarter?

BioVie Inc. (NASDAQ:BIVI) announced its quarterly earnings data on Friday, January, 29th. The company reported ($0.22) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.10.
View BioVie's earnings history

What price target have analysts set for BIVI?

1 equities research analysts have issued twelve-month price targets for BioVie's stock. Their forecasts range from $47.00 to $47.00. On average, they anticipate BioVie's stock price to reach $47.00 in the next year. This suggests a possible upside of 218.0% from the stock's current price.
View analysts' price targets for BioVie
or view top-rated stocks among Wall Street analysts.

Who are BioVie's key executives?

BioVie's management team includes the following people:
  • Mr. Terren S. Peizer, Chairman & CEO (Age 61)
  • Mr. Jonathan M. Adams M.B.A., MBA, Pres & COO (Age 58, Pay $250k)
  • Ms. Joanne Wendy Kim CPA, CFO & Corp. Sec. (Age 66)
  • Dr. Penelope Markham, Chief Scientific Officer (Age 55)
  • Ms. Denise Smith, Sr. VP of Manufacturing & Devel.

Who are some of BioVie's key competitors?

What is BioVie's stock symbol?

BioVie trades on the NASDAQ under the ticker symbol "BIVI."

Who are BioVie's major shareholders?

BioVie's stock is owned by many different institutional and retail investors. Top institutional shareholders include HN Saltoro Capital LP (0.11%).
View institutional ownership trends for BioVie

Which major investors are buying BioVie stock?

BIVI stock was purchased by a variety of institutional investors in the last quarter, including HN Saltoro Capital LP.
View insider buying and selling activity for BioVie
or or view top insider-buying stocks.

How do I buy shares of BioVie?

Shares of BIVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioVie's stock price today?

One share of BIVI stock can currently be purchased for approximately $14.78.

How much money does BioVie make?

BioVie has a market capitalization of $205.68 million.

How many employees does BioVie have?

BioVie employs 2 workers across the globe.

What is BioVie's official website?

The official website for BioVie is www.biovieinc.com.

How can I contact BioVie?

The company can be reached via phone at 312 283 5793.

This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.